CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company

Analyzing ownership data of a company like CytomX Therapeutics, Inc. can provide insights into future performance. Institutional investors hold a significant stake, influencing market decisions. Hedge funds and insiders also play key roles. Considering analyst forecasts alongside ownership research can help in evaluating a company's potential.